Assessing cognitive decline using a new screening tool
Validation and Clinical Usability of a New Screening Tool: MASCoD - Multidimensional Assessment of Subjective Cognitive Decline
NA · Istituti Clinici Scientifici Maugeri SpA · NCT05815329
This study is testing a new tool to see if it can help people who notice their thinking skills declining, without any other brain problems, and whether cognitive training can help them improve.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 55 Years and up |
| Sex | All |
| Sponsor | Istituti Clinici Scientifici Maugeri SpA (other) |
| Locations | 1 site (Montescano, Pavia) |
| Trial ID | NCT05815329 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of a new screening tool called MASCoD (Multidimensional Assessment of Subjective Cognitive Decline) in detecting and monitoring subjective cognitive decline (SCD). The study will analyze the correlation between MASCoD scores and neuropsychological evaluations, as well as brain imaging using 18F-FDG-PET to predict the risk of developing severe cognitive decline. Participants will undergo cognitive training interventions to assess the potential benefits of rehabilitation in managing SCD. The study focuses on individuals who report cognitive decline without any other neurological issues.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 55 years old who report subjective cognitive decline without any other cognitive or neurological issues.
Not a fit: Patients with serious clinical conditions, prior psychiatric disorders, or established cognitive decline may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable method for early detection of cognitive decline, potentially improving patient outcomes through timely interventions.
How similar studies have performed: While there are limited studies focusing on subjective cognitive decline, the approach of using a multidimensional screening tool is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * reported subjective cognitive decline without any other cognitive or neurological issue, * Italian education, * adult (\> 55 years old), * understanding of research aims, * signed informed consent, * participation on a voluntary and non-payied bases. Exclusion Criteria: * serious clinical conditions (e.g. severe cardiac and respiratory problems, neoplasia) * prior diagnosis of psychiatric disorders according to DSM-5, * prior diagnosis of cognitive decline, * relevant visuo-perceptive or hearing deficits, * illiteracy or relapse in illiteracy, * refusal to partake in the research.
Where this trial is running
Montescano, Pavia
- ICS Maugeri Montescano Institute — Montescano, Pavia, Italy (RECRUITING)
Study contacts
- Study coordinator: Cira Fundarò, Neurologist
- Email: cira.fundaro@icsmaugeri.it
- Phone: 0385247268
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cognitive Decline, mild cognitive impairment, subjective cognitive decline, neuropsychological rehabilitation